Kroeger, N. Et Al. 2021. Impact of Prior Jak-Inhibitor Therapy With Ruxolitinib on Outcome After Allogeneic Stem Cell Transplantation For Myelofibrosis. A Large EBMT-CMWP Study. BONE MARROW TRANSPLANTATION , vol.56 , 143-144.

Kroeger, N., Sbianchi, G., Sirait, T., Beelen, D., Passweg, J., Robin, M., ... Vrhovac, R.(2021). Impact of Prior Jak-Inhibitor Therapy With Ruxolitinib on Outcome After Allogeneic Stem Cell Transplantation For Myelofibrosis. A Large EBMT-CMWP Study. BONE MARROW TRANSPLANTATION , vol.56, 143-144.

Kroeger, Nicolaus Et Al. "Impact of Prior Jak-Inhibitor Therapy With Ruxolitinib on Outcome After Allogeneic Stem Cell Transplantation For Myelofibrosis. A Large EBMT-CMWP Study," BONE MARROW TRANSPLANTATION , vol.56, 143-144, 2021

Kroeger, Nicolaus Et Al. "Impact of Prior Jak-Inhibitor Therapy With Ruxolitinib on Outcome After Allogeneic Stem Cell Transplantation For Myelofibrosis. A Large EBMT-CMWP Study." BONE MARROW TRANSPLANTATION , vol.56, pp.143-144, 2021

Kroeger, N. Et Al. (2021) . "Impact of Prior Jak-Inhibitor Therapy With Ruxolitinib on Outcome After Allogeneic Stem Cell Transplantation For Myelofibrosis. A Large EBMT-CMWP Study." BONE MARROW TRANSPLANTATION , vol.56, pp.143-144.

@article{article, author={Nicolaus Kroeger Et Al. }, title={Impact of Prior Jak-Inhibitor Therapy With Ruxolitinib on Outcome After Allogeneic Stem Cell Transplantation For Myelofibrosis. A Large EBMT-CMWP Study}, journal={BONE MARROW TRANSPLANTATION}, year=2021, pages={143-144} }